Daily adaptation supported 17-fraction definitive chemoradiotherapy for cervical cancer
Daily online adaptation improved pelvic target coverage during 17-fraction cervical chemoradiotherapy, with 10% grade ≥3 gastrointestinal toxicity.
Daily online adaptation improved pelvic target coverage during 17-fraction cervical chemoradiotherapy, with 10% grade ≥3 gastrointestinal toxicity.
Grade 2 dermatitis fell from 38.6% to 25.3% with 16-fraction whole-breast radiotherapy plus simultaneous integrated boost.
40 Gy in 15 fractions did not increase three-year arm lymphedema or compromise recurrence and mortality outcomes compared with 50 Gy.
Radiation reached 60 Gy in 15 fractions with adjuvant atezolizumab, while concurrent dosing was followed by HSV-1 reactivation in three of five patients.
BED >37.5 Gy improved symptomatic control, while 6-month local control remained 46% in frail, elderly, or metastatic rectal cancer.
High-dose-rate brachytherapy monotherapy achieved 86% biochemical control at median 13-year follow-up in localized prostate cancer.
A conventional-fractionation model produced clinically acceptable moderately hypofractionated prostate plans, with comparable overall quality and slightly reduced target homogeneity.